Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Clinical trial NCT04285086 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04285086
- Sponsor
- PharmaEssentia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-25
- Primary completion
- 2024-11-12
- Enrollment
- 174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.